Results 91 to 100 of about 21,604,258 (289)
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen +10 more
wiley +1 more source
ERα–PADI4–CXCL8 Axis Drives MDSC‐Mediated Immune Evasion in Anaplastic Thyroid Carcinoma
MAPK‐driven ligand‐independent ERα activation drives PADI4 transcription and translation. This enzyme then modifies CXCL8 chemokines through citrullination, generating a potent chemoattractant gradient specifically for myeloid‐derived suppressor cells.
Dongdong Zhang +5 more
wiley +1 more source
Clinical advances on chimeric antigen receptor T cell therapy for glioblastoma
Chimeric antigen receptor T cell (CAR⁃T) is a kind of genetically engineered T cells that can express tumor⁃associated antigen (TAA) specific receptors on its surface. The modified T cells can be used for cancer therapy by targeting its specific receptor
Jun CAO +4 more
doaj
Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL), a common type of B cell chronic lymphoproliferative disorder in adults, has witnessed enormous development in its treatment in recent years.
Yixin Zou, Wei Xu, Jianyong Li
doaj +1 more source
SPRED2 Negatively Regulates CD8+ T Cell‐Mediated Antitumor Immunity in Breast Cancer
Sprouty‑related EVH1 domain containing 2 (SPRED2) restrains Ras/Raf/ERK signaling in CD8+ T cells. Host SPRED2 deficiency enhances T‐cell survival, cytotoxicity, and memory‐like phenotypes, reducing primary tumor growth and endpoint lung metastatic burden in breast cancer models.
Miao Tian +8 more
wiley +1 more source
SIMPLE SUMMARY: Approved chimeric antigen receptor (CAR) T cells recognize and bind to only one tumor target (single-targeted CAR T cells, Si-CART) on cancer cells by the special receptor and followed with activation, thus removing cancers from patients.
Zhengdong Li +7 more
core +1 more source
A deep‐learning‐designed binder is fused to a combinatorial degron to create a binder‐degron chimera (bdC) that recruits the CUL2‐RING ubiquitin ligase complex. Encapsulation in a prostate‐cancer‐targeted, CD47‐camouflaged nanocarrier enables tumor‐specific in situ bdC expression, triggering GPX4 degradation and ferroptosis, thereby establishing a ...
Si‐Han Zhang +8 more
wiley +1 more source
A bioactive self‐delivering SNAP‐TAC platform responds to tumor‐associated cathepsin B and glutathione, enabling in situ bioorthogonal synthesis of a BRD4‐degrading proteolysis‐targeting chimera within the tumor microenvironment. The resulting BRD4 degradation and PD‐L1 downregulation synergize with photodynamic therapy‐induced immunogenic cell death ...
Shiqin Jian +14 more
wiley +1 more source
An engineered peptide self‐assembled nanofiber platform, designed to replicate STING–cGAMP binding motifs, facilitates pH‐responsive cytosolic delivery of cGAMP, enhances the endoplasmic reticulum with high efficiency, and robustly activates the STING pathway.
Yubin He +6 more
wiley +1 more source
Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (CRISPR/Cas9) system, an RNA-guided DNA targeting technology, is triggering a revolution in the field of biology.
Jiangtao Ren, Yangbing Zhao
doaj +1 more source

